Meeting Banner
Abstract #1158

Multi-modality molecular imaging with hyperpolarized [1-13C]pyruvate MRSI and 18FDG-PET of early tumor response to a novel TRAIL agonist (MEDI3039)

Richard L Hesketh1, Jiazheng Wang1, Alan J Wright1, Maria Fala1, Susana Ros1, Jodi Miller1, David Y Lewis1,2, and Kevin M Brindle1,3

1CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, 2CRUK Beatson Institute, Glasgow, United Kingdom, 3Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

This study compared the capability of 3D magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized [1-13C]pyruvate metabolism and 18FDG-PET to detect early responses to a TRAIL agonist (Medimmune MEDI3039) in Colo205 colorectal cancer and MDA-MB-231 triple-negative breast cancer xenograft models expressing luciferase and mStrawberry fluorescent protein. 24 hours after treatment, bioluminescence and hyperpolarized lactate/pyruvate ratio decreased significantly in all treated animals, preceding decreases in tumor volume. Conversely, 18FDG-PET did not detect treatment response. This suggests that for some tumors hyperpolarized [1-13C]pyruvate may be an improvement on 18FDG-PET and RECIST for the early detection of treatment response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here